Video Library

Dr. Mullins says that methods for evaluating comparative- and cost-effectiveness of treatment are evolving. He points out that side effects may represent significant burdens to patients and need to be considered to understand the true value of using improved therapies that reduce side effects.
Dr. Mullins confirms that value in healthcare is incredibly important to both patients and insurance companies. The development of many new treatment options in the field of oncology makes it a prime place to look for value. Value can be determined by comparing evidence of cost and evidence of improved health outcomes.
Dr. Stainthorpe explains that the single payer perspective allows for negotiated terms and equality of access; however, they do not necessarily drive down costs the way multiple payers can.
Gary Owens explains the importance of the oncology pharmacist as part of the oncology care team. He suggests that the role of the oncology pharmacist should evolve to have more patient interaction due to their unique knowledge of cancer drugs—their interactions, toxicities, and side effects.
Dr. Stainthorpe shares his belief that when it comes to care decisions, oncology patients should be provided with information about the benefits/outcomes/consequences and cost of their care.
Oncologists should be guided by the research that is being done around outcomes, benefit, and society impact when making value-based care decisions, says Dr. Stainthorpe.
Dr. Mullins speaks about the Academy of Managed Care Pharmacy (AMCP) and the importance of their input regarding the value of healthcare in oncology. This organization is in a good position to inform policymakers about the cost-effectiveness of various cancer therapies.
Dr. Mullins dismisses the perception that quality and cost must always be at odds when it comes to cancer treatment. He points out that providing lifesaving treatments that provide a high quality of life do generally come at a higher cost. However, providing poor quality care often leads to wasteful spending because more is spent on fixing problems that are created by the low quality of care.
Gary Owens discusses the complexities of cost-sharing as it relates to cancer care. He cites the fact that the cost of cancer care has increased dramatically and benefit designs have decreased, disproportionately affecting cancer patients. He also talks about AVBCC's role in moving the discussion toward solving the issues surrounding the cost of cancer treatment.
Andrew Stainthorpe, PhD, PASLU, NICE, talks about why the FDA should not take drug cost into account when weighing the approval of expensive medications.
Page 3 of 9
Results 21 - 30 of 89
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME